Methods for the rapid detection of the presence or absence of Hepatitis B Virus (HBV) in a biological or non-biological sample are described. The methods can include performing an amplifying step, a hybridizing step, and a detecting step. Furthermore, primers, competitive blocking oligonucleotides, and probes targeting HBV (in particular HBV RNA, in particular, HBV RNA transcribed from cccDNA, such as pgRNA) and kits are provided that are designed for the detection of HBV (in particular HBV RNA, in particular, HBV RNA transcribed from cccDNA, such as pgRNA).

The present invention provides a method of quantification of a target nucleic acid, using at least any two of the genes SYT10, EPHA3, PLEKHF1 and KBTBD4 as control genes. In particular, the combination of the genes SYT10, EPHA3, PLEKHF1 and KBTBD4, known as the 4Plex, is provided as a control for nucleic acid quantification. The 4Plex has particular utility as a control for nucleic acid quantification by methylation-specific droplet digital PCR.

The present disclosure provides methods and compositions to watermark chemical compounds. The disclosed methods provide methods whereby the unique watermark allows identification of substantially similar chemical reactions in a single qPCR reaction mixture. Further, the disclosure provides methods whereby the unique watermark allows for identification of reaction mixtures.

The present disclosure provides methods and compositions to watermark chemical compounds. The disclosed methods provide methods whereby the unique watermark allows identification of substantially similar chemical reactions in a single qPCR reaction mixture. Further, the disclosure provides methods whereby the unique watermark allows for identification of reaction mixtures.

The present invention relates to an in vitro method for identifying and/or characterizing one or more mutations in a hotspot mutation sequence of at least one ESR1 target fragment from a DNA sample,

said method comprising subjecting the DNA sample to a drop-off digital polymerase chain reaction (PCR) in the presence of a PCR solution comprising: a pair of primers suitable for amplifying an ESR1 target fragment; an oligonucleotide reference (REF) hydrolysis probe, labeled with a fluorophore, wherein said REF oligonucleotide probe is complementary to a wild-type sequence of the target fragment located outside of the hotspot mutation sequence; an oligonucleotide hotspot (HOTSPOT) hydrolysis probe, labeled with another fluorophore, wherein said oligonucleotide HOTSPOT probe is complementary to a wild-type sequence of the hotspot mutation sequence of the target DNA fragment.

The present invention relates to an in vitro method for identifying and/or characterizing one or more mutations in a hotspot mutation sequence of at least one ESR1 target fragment from a DNA sample,

said method comprising subjecting the DNA sample to a drop-off digital polymerase chain reaction (PCR) in the presence of a PCR solution comprising: a pair of primers suitable for amplifying an ESR1 target fragment; an oligonucleotide reference (REF) hydrolysis probe, labeled with a fluorophore, wherein said REF oligonucleotide probe is complementary to a wild-type sequence of the target fragment located outside of the hotspot mutation sequence; an oligonucleotide hotspot (HOTSPOT) hydrolysis probe, labeled with another fluorophore, wherein said oligonucleotide HOTSPOT probe is complementary to a wild-type sequence of the hotspot mutation sequence of the target DNA fragment.

Provided herein are compositions, methods and uses that relate to an easy, accurate and reliable dual or duplex assay that determines both protein and nucleic acid amounts in a viral preparation in a single container and further determines full versus empty virion content.

Provided herein are compositions, methods and uses that relate to an easy, accurate and reliable dual or duplex assay that determines both protein and nucleic acid amounts in a viral preparation in a single container and further determines full versus empty virion content.

Provided is a device including: a plurality of wells; a reagent composition located in each of the wells and containing an amplifiable reagent in a specific copy number; and two or more groups into which the wells are divided to have the amplifiable reagent located in the same specific copy number but to be varied in composition of the reagent composition except for the specific copy number. Preferably, composition except for the specific copy number of the amplifiable reagent includes at least any one of primer and amplifying reagent. More preferably, the device includes two or more groups varied in the specific copy number. Yet more preferably, the groups of wells include at least a negative control group in which the specific copy number of the amplifiable reagent is 0, and a group in which the specific copy number of the amplifiable reagent is close to the limit of detection.

Provided is a device including: a plurality of wells; a reagent composition located in each of the wells and containing an amplifiable reagent in a specific copy number; and two or more groups into which the wells are divided to have the amplifiable reagent located in the same specific copy number but to be varied in composition of the reagent composition except for the specific copy number. Preferably, composition except for the specific copy number of the amplifiable reagent includes at least any one of primer and amplifying reagent. More preferably, the device includes two or more groups varied in the specific copy number. Yet more preferably, the groups of wells include at least a negative control group in which the specific copy number of the amplifiable reagent is 0, and a group in which the specific copy number of the amplifiable reagent is close to the limit of detection.